News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Merck & Co., Inc. Withdraws Bid For EU Regulatory OK Of Asthma Medicine
November 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Merck & Co. (MRK) has withdrawn its application for European regulatory approval of an asthma treatment, citing outstanding questions by regulators.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Merck & Co.
MORE ON THIS TOPIC
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
March 9, 2026
·
3 min read
·
Tristan Manalac
Rare diseases
Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts
March 9, 2026
·
3 min read
·
Tristan Manalac
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
March 9, 2026
·
2 min read
·
Tristan Manalac
